Neutralizing Monoclonal Antibody Use and Spectacular COVID-19 Outcomes

Mortality Reduction Seen Across Products and Variants

By Peter A. McCullough, MD, MPH

It is tempting to paint everything with a broad brush. For example: “everything the government did

on pandemic response did was terrible.” I can tell you first hand the development of monoclonal antibodies against SARS-CoV-2 was a clear winner. Dr. Ralph Baric at UNC Chapel Hill envisioned we would use monoclonal antibodies for his chimeric creation (SARS-CoV-2) since he tested them in the Wuhan Institute of Virology lab and described them in his 2015 papers. I wonder why Baric has been so quiet about this area of “counter-measure” success in pandemic response.

Ambrose et al, reporting a stunning 88 and 86% 14- and 30-day mortality reductions, respectively, in largely unvaccinated patients with acute COVID-19. The array of products was robust and despite difficulty with access and premature market withdrawal, those who received infusions had terrific outcomes. While the effect size could be inflated by selection or treatment bias, confounding, or both—it was clear that the unvaccinated benefitted greatly.